Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma

Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma

Background The majority of patients with melanoma develop immune-related adverse events (irAEs), and over half do not respond to anti-PD-1 (Programmed cell death protein 1) checkpoint inhibitor (CPI) immunotherapy. Accurate predictive biomarkers for both response to therapy and development of irAEs...

Full description

Saved in:
Bibliographic Details
Main Authors: Akshay Patel, Yin Wu, Sophie Papa, Sean Whittaker, Ashley Di Meo, Ioannis Prassas, Katie E Lacy, Eleftherios P Diamandis, Sophia N Karagiannis, Thomas J Tull, Sophia Tsoka, Dhruva Biswas, Jitesh Chauhan, Katie Stoker, Zena N Willsmore, Lucy Booth, Amanda Fitzpartick, Matthaios Kapiris, Esperanza Perucha, Gary W Middleton
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e011682.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/5/e011682.full

Similar Items